Ignasi Pau‐Charles

Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm^®- and placebo-controlled trial (BRIDGE)

Ulrich Mrowietz, Jacek C. Szepietowski, Robert Loewe et al. · British Journal of Dermatology · 2016 · 147 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +12

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase <scp>III</scp> clinical trials (re <scp>SURFACE</scp> 1 and re <scp>SURFACE</scp> 2) through 148 weeks

Kristian Reich, Richard B. Warren, Lars Iversen et al. · British Journal of Dermatology · 2019 · 143 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

Diamant Thaçi, Stefano Piaserico, Richard B. Warren et al. · British Journal of Dermatology · 2021 · 96 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

First-line treatment in lymphomatoid papulosis: a retrospective multicentre study

Ricardo Fernández‐de‐Misa, B. Hernández‐Machín, Octavio Servitje et al. · Clinical and Experimental Dermatology · 2017 · 40 citations · Full text

Medicine, Dermatology, Oncology +14

Anti‐<scp>MDA</scp>5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy

Ignasi Pau‐Charles, Pedro Moreno, K. Ortiz‐Ibáñez et al. · Journal of the European Academy of Dermatology and Venereology · 2013 · 27 citations

Medicine, Dermatology, Pathology +16